Page 1

Exhibit 99.1 ADC THERAPEUTICS ADC Therapeutics Reports Fourth Quarter and Year - End 2020 Financial Results and Provides Business Updates Lonca BLA accepted by FDA with priority review ; PDUFA date May 21 , 2021 Commercial , medical affairs , CMC and support functions prepared for potential Lonca approval Updated data for lead programs Lonca and Cami presented at American Society of Hematology ( ASH ) Annual Meeting in December 2020 Overland ADCT BioPharma launched to develop and commercialize select products in greater China and Singapore Company to host conference call today at 8:30 a.m. EDT Lausanne , Switzerland , March 18 , 2021 - ADC Therapeutics SA ( NYSE : ADCT ) , a late clinical - stage oncology - focused biotechnology company pioneering the development and commercialization of potent and targeted antibody drug conjugates ( ADCs ) for patients with hematological malignancies and solid tumors , today reported financial results for the fourth quarter and fiscal year ended December 31 , 2020 and provided business updates . " The ADC Therapeutics team is well - positioned to execute on our goals for 2021 after a year of significant progress and achievements across the company in 2020 , " said Chris Martin , Chief Executive Officer of ADC Therapeutics . " As we approach the May 21 , 2021 PDUFA date and planned commercial launch of our lead therapeutic candidate , Lonca , we have recruited a team of industry veterans to advance our commercial , medical affairs and CMC goal of rapidly bringing Lonca to patients with relapsed or refractory diffuse large B - cell lymphoma who are in desperate need of new treatment options . For our second lead program , Cami , we completed enrollment in our pivotal Phase 2 trial , bringing us one step closer to potentially addressing an unmet need in heavily pre - treated Hodgkin lymphoma patients . We look forward to reporting updated interim data from the trial in the first half of this year . Finally , we continued to develop our strong research pipeline and licensed advanced technologies for next- generation ADC research and development for patients with difficult - to - treat hematologic and solid tumor cancers . " Recent Highlights from Two Lead Programs Loncastuximab Tesirine ( Lonca ) • Executing commercial strategy for mid - 2021 launch in 3L + relapsed or refractory diffuse large B - cell lymphoma ( DLBCL ) : The Company's commercial and medical affairs organizations are hired , trained and finalizing launch preparations in anticipation of potential U.S. Food and Drug Administration ( FDA ) approval in mid - 2021 . From a CMC perspective , the Company has commercial drug product ready for potential launch . FDA PDUFA date set for May 21 , 2021 : In November 2020 , the FDA accepted the Company's Biologics License Application ( BLA ) filing for Lonca for the treatment of patients with relapsed